Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Equity Ratio (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Equity Ratio data on record, last reported at 0.87 in Q4 2025.

  • For Q4 2025, Equity Ratio rose 37.74% year-over-year to 0.87; the TTM value through Dec 2025 reached 0.87, up 37.74%, while the annual FY2025 figure was 0.87, 37.74% up from the prior year.
  • Equity Ratio reached 0.87 in Q4 2025 per TNGX's latest filing, up from 0.76 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.87 in Q4 2025 and bottomed at 0.33 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.62, with a median of 0.64 recorded in 2024.
  • Peak YoY movement for Equity Ratio: surged 2221.27% in 2021, then dropped 17.16% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.69 in 2021, then decreased by 17.08% to 0.57 in 2022, then grew by 10.0% to 0.63 in 2023, then grew by 0.27% to 0.63 in 2024, then skyrocketed by 37.74% to 0.87 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.87 in Q4 2025, 0.76 in Q3 2025, and 0.57 in Q2 2025.